A clinical trial to compare the investigational drug EG-1962 with standard of care oral nimodipine in adults with Subarachnoid Hemorrhage caused by a ruptured aneurysm.
- Conditions
- Aneurysmal subarachnoid hemorrhage (aSAH)MedDRA version: 20.1Level: LLTClassification code 10072200Term: Asymptomatic subarachnoid hemorrhageSystem Organ Class: 100000004863MedDRA version: 20.1Level: LLTClassification code 10042320Term: Subarachnoid hemorrhageSystem Organ Class: 100000004863Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Registration Number
- EUCTR2015-005033-53-DE
- Lead Sponsor
- Edge Therapeutics, Inc
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 282
1. Male or female between the ages of 18 to 75 years, inclusive
2. Ruptured saccular aneurysm confirmed by angiography (CTA, MRA or catheter) and repaired
by neurosurgical clipping or endovascular coiling
3. Subarachnoid hemorrhage on CT scan (pre-repair) of grade 2-4 on the modified Fisher scale
(diffuse [clot present in both hemispheres] thick or thin, or local thick)
4. External ventricular drain in place
5. WFNS grade 2, 3, or 4 assessed during the Pre-randomization Phase after repair of the
aneurysm but prior to randomization
6. The subject must be able to receive intraventricular IP within 48 hours after the onset of aSAH and within 4 hours after the start time of intraventricular IP suspension in the pharmacy. Onset of aSAH is defined as the time the subject experiences the first symptom of aSAH (e.g., severe headache or loss of consciousness reported either by the subject or by a witness). If found unconscious, the onset of SAH is defined as the time the subject was last known normal
7. Female subjects of child-bearing potential must have a negative pregnancy test (urine or serum) during the Pre-randomization Phase and must agree to use adequate birth control for at least 30 days following the end of the Treatment Period. Male subjects must agree to use adequate birth for at least 30 days after the end of the Treatment Period
8. Signed informed consent from the subject or the subject’s legal representative after the
completion of aneurysm repair but prior to any study-specific procedures being performed
9. Able and willing to comply with follow up visit schedule
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 249
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 125
1. Major complication during aneurysm repair such as, but not limited to, massive intraoperative hemorrhage, brain swelling, arterial occlusion, or inability to secure the ruptured aneurysm
2. Angiographic vasospasm prior to randomization
3. Clinical or radiological evidence of a cerebral infarction with neurological deficit
4. Increased intracranial (ICP) pressure >30 mm Hg lasting >4 hours anytime during the Prerandomization Phase
5. Substantial intraventricular hemorrhage
6. Aneurysm repair requiring flow diverting stent or stent-assisted coiling and dual antiplatelet
therapy
7. Subject is expected to undergo repair of additional aneurysms within 90 days in cases where
multiple aneurysms were identified during the Pre-randomization PhaseHemodynamically unstable during the Pre-randomization Phase (i.e., systolic blood pressure (SBP) <100 mm Hg, requiring >6 L colloid, or crystalloid fluid resuscitation)
9. Cardiopulmonary resuscitation was required during the Pre-randomization Phase
10. Symptoms or electrocardiogram (ECG) signs of acute myocardial infarction or unstable angina pectoris prior to randomization
11. Electrocardiogram evidence and/or physical findings compatible with second or third degree heart block or of cardiac arrhythmia associated with hemodynamic instability
12. Echocardiogram, if performed as part of standard of care before randomization, revealing a left ventricular ejection fraction <40%
13. Severe or unstable concomitant condition or disease (e.g., known significant neurologic deficit, cancer, hematologic or coronary disease), or chronic condition (e.g., liver disease, kidney disease or psychiatric disorder), that, in the opinion of the investigator, may increase the risk associated with study participation or IP administration, or may interfere with the interpretation of study results
14. Subjects who have received an investigational product or participated in another interventional clinical study within 30 days prior to randomization. Subjects participating in a
non-interventional study that has no bearing on assessment of EG-1962 or enteral nimodipine
may be enrolled per guidelines of the local Institutional Review Board (IRB)/Independent
Ethics Committee (IEC)
15. Known hypersensitivity to nimodipine or other dihydropyridine calcium channel antagonists, poly-D, L-lactide-co-glycolide (PLGA), or hyaluronic acid
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To compare the efficacy of intraventricular EG-1962 to standard of care oral nimodipine in subjects with aSAH.;Secondary Objective: To determine the safety of intraventricular EG-1962 compared to standard of care oral nimodipine in subjects with aSAH.;Primary end point(s): Proportion of subjects with a favorable outcome measured on the Extended Glasgow Outcome Scale (GOSE) at Day 90 by a blinded assessor;Timepoint(s) of evaluation of this end point: Day 90
- Secondary Outcome Measures
Name Time Method Secondary end point(s): Proportion of subjects with favorable neurocognitive outcome at Day 90 measured by the Montreal Cognitive Assessment (MoCA) by a blinded assessor;Timepoint(s) of evaluation of this end point: Day 90